MarketPeel
Insider Trading Intelligence
JM

John S. Montalbano

ABCL
DIRECTOR · ABCELLERA BIOLOGICS INC. · CIK 0001834423
FILING MIX · LIFETIME100%/0%
BUYS
18
SELLS
0
TOTAL VALUE
$1.48M
COMPANIES
1
ACTIVE SINCE
Nov 2020
HOLDINGS NOW
1,141,544
AVG SELL PX
TRADE KIND
SHOWING 18 / 18
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
10 backtested trades · 8 horizons · 4 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by John S. Montalbano, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d10+50.00%-1.27%-0.44%-0.83%-1.91%
14d10+50.00%-1.62%+1.63%-3.25%-0.56%
30d10+50.00%+4.46%+1.51%+2.95%+1.48%
60d10+30.00%+2.13%+2.46%-0.33%-7.69%
90d10+40.00%-3.38%+5.33%-8.71%-9.21%
180d10+50.00%+9.51%+9.18%-3.38%-20.66%
1y10(1 pending)+22.22%-16.78%+17.25%-34.03%-25.31%
2y10(3 pending)+14.29%-44.54%+25.40%-69.94%-66.05%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
ABCL · 1,141,544 shares · as of Jun 11, 2026
0285,386570,772856,1581,141,544202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 18 buys / 0 sellsCOVERAGE · 23 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ABCL
ABCELLERA BIOLOGICS INC.
PURCHASEGRANT
Stock grant
111,7011,141,544Jun 11, 2026Jun 12, 2026View →
ABCL
ABCELLERA BIOLOGICS INC.
PURCHASE
20,000$4.77$95.4K241,000May 14, 2026May 18, 2026View →
ABCL
ABCELLERA BIOLOGICS INC.
PURCHASE
50,000$3.57$178.5K221,000Nov 26, 2025Nov 26, 2025View →
ABCL
ABCELLERA BIOLOGICS INC.
PURCHASEGRANT
Stock grant
238,8641,029,843Jun 12, 2025Jun 16, 2025View →
ABCL
ABCELLERA BIOLOGICS INC.
PURCHASE
25,000$2.30$57.5K171,000Mar 10, 2025Mar 10, 2025View →
ABCL
ABCELLERA BIOLOGICS INC.
PURCHASE
60,000$2.34$140.6K146,000Mar 6, 2025Mar 7, 2025View →
ABCL
ABCELLERA BIOLOGICS INC.
PURCHASEGRANT
Stock grant
163,934790,979Jun 21, 2024Jun 24, 2024View →
ABCL
ABCELLERA BIOLOGICS INC.
PURCHASE
10,000$4.46$44.6K86,000Nov 8, 2023Nov 8, 2023View →
ABCL
ABCELLERA BIOLOGICS INC.
PURCHASE
20,000$4.64$92.8K76,000Nov 6, 2023Nov 8, 2023View →
ABCL
ABCELLERA BIOLOGICS INC.
PURCHASEGRANT
Stock grant
47,231627,045Dec 1, 2022Dec 5, 2022View →
ABCL
ABCELLERA BIOLOGICS INC.
PURCHASE
10,000$8.54$85.4K56,000Mar 4, 2022Mar 4, 2022View →
ABCL
ABCELLERA BIOLOGICS INC.
PURCHASE
20,000$9.05$181.0K46,000Mar 1, 2022Mar 3, 2022View →
ABCL
ABCELLERA BIOLOGICS INC.
PURCHASEGRANT
Stock grant
45,532579,814Dec 7, 2021Dec 10, 2021View →
ABCL
ABCELLERA BIOLOGICS INC.
PURCHASEGRANT
Stock grant
34,282534,282Aug 27, 2021Dec 10, 2021View →
ABCL
ABCELLERA BIOLOGICS INC.
PURCHASE
6,000$17.23$103.4K26,000Aug 16, 2021Aug 17, 2021View →
ABCL
ABCELLERA BIOLOGICS INC.
PURCHASE
20,000$20.00$400.0K20,000Dec 15, 2020Dec 17, 2020View →
ABCL
ABCELLERA BIOLOGICS INC.
PURCHASE
5,000$20.00$100.0K5,000Dec 15, 2020Dec 17, 2020View →
ABCL
ABCELLERA BIOLOGICS INC.
PURCHASEGRANT
Stock grant
500,000500,000Nov 18, 2020Dec 17, 2020View →
Other insiders · ABCL
Loading peer insiders…
About this filer
CIK 0001834423
ROLE
Director
PRIMARY
ABCL
COMPANIES
1
ACTIVE SINCE
Nov 2020
MARKETPEEL · /INSIDER/0001834423DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback